Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Underperformed due to a 20% revenue decline in its engineering segment and rising investor fears regarding oral GLP-1 alternatives.
— Derek Johnston
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Stevanato Group S.p.A.
The strongest performer was pharmaceutical glass manufacturer Stevanto (STVN). The company’s products...
STVN provides drug containment and delivery solutions to pharmaceutical and biotechnology companies.
As businesses with unique and uncorrelated return drivers, Daikin and Corteva complement our existing Reversionary investments, such as pharmaceutical glass manufacturer Stevanato (STVN